natgillin/translations-raw huggingface dataset:
Thorinane 8,000 IU (80 mg) in 0.8 mL
Thorinane 8000 IU (80 mg) u 0,8 ml
Thorinane 8,000 IU (80 mg) in 0.8 mL injection enoxaparin sodium
Thorinane 8000 IU (80 mg) u 0,8 ml, injekcija enoksaparin-natrij s.c., i.v. ili u arteriju
Thorinane 8,000 IU (80 mg) in 0.8 mL solution for injection in pre-filled syringe
Thorinane 8000 IU u 0,8 ml, otopina za injekciju u napunjenoj štrcaljki
Thorinane 8,000 IU (80 mg) in 0.8 mL solution for injection in pre-filled syringe enoxaparin sodium
Thorinane 8000 IU (80 mg) u 0,8 ml, otopina za injekciju u napunjenoj štrcaljki enoksaparin-natrij
Thorinane contains sodium
Thorinane sadrži natrij
Thorinane has no influence on the ability to drive and use machines.
Thorinane ne utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Thorinane is a ‘biosimilar medicine’.
Thorinane je „biosličan lijek”.
Thorinane is indicated for adults for:
Thorinane je indiciran u odraslih za:
Thorinane must not be administered by the intramuscular route.
Thorinane se ne smije davati intramuskularno.
Thorinane should not be mixed with any other injections or infusions.
Thorinane se ne smije miješati s drugim injekcijama ili infuzijama
Thorinane should not be mixed with any other injections or infusions.
Thorinane se ne smije miješati s drugim injekcijama ili infuzijama.
Those effects are described in the cisplatin patient information.
Te nuspojave opisane su u Uputi o lijeku cisplatin.
Those patients studied all had CD4+ cell counts greater than 250 x 106 cells/l (N = 22; see section 4.5).
Svi bolesnici u ispitivanju imali su broj CD4+ stanica veći od 250 x 106 stanica/l (N = 22; vidjeti dio 4.5).
Those serious adverse reactions attributed to TRISENOX included APL differentiation syndrome (3), leukocytosis (3), prolonged QT interval (4, 1 with torsade de pointes), atrial fibrillation/atrial flutter (1), hyperglycaemia (2) and a variety of serious adverse reactions related to haemorrhage, infections, pain, diarrhoea, nausea.
Te ozbiljne nuspojave pripisane TRISENOXU uključivale su sindrom diferencijacije APL-a (3), leukocitozu (3), produljeni QT interval (4, 1 s torsade de pointes), fibrilaciju atrija/undulaciju atrija (1), hiperglikemiju (2) i razne ozbiljne nuspojave povezane s krvarenjem, infekcijama, boli, proljevom, mučninom.
Those signs are usually transient and disappear within 24 hours of the application; if they take longer to disappear consult your veterinarian.
Ti znakovi obično su prolazni i nestaju unutar 24 sata nakon primjene; ako njihovo povlačenje potraje duže, obratite se svom veterinaru.
Those trials have shown that the safety profile of the liquid formulation is comparable to the lyophilised formulation.
Ta su ispitivanja pokazala da je sigurnosni profil tekuće formulacije usporediv s liofiliziranom formulacijom.
Those which have not yet been entered should be reported in the following S- PSUR.
O onima koji nisu bili uneseni do tada bi se trebalo izvijestiti u sljedećem S-PSUR-u.
Those with HBV DNA levels greater than 200 copies/mL at 6 months (24 weeks) of lamivudine therapy had a 60 % chance of developing the YMDD mutant compared with 8 % of those with HBV DNA levels less than 200 copies/mL at 24 weeks of lamivudine therapy.
Mogućnost razvoja YMDD tipa virusa iznosila je 60% u bolesnika čije su razine HBK DNK bile više od 200 kopija/ml nakon 6 mjeseci (24 tjedna) liječenja lamivudinom, u odnosu na 8% u onih čije su razine HBV DNK bile manje od 200 kopija/ml nakon 24 tjedna liječenja lamivudinom.
Though less potent than naltrexone,
Iako slabije djelotvoran od naltreksona,
Though the number of patients included was limited and with high variability, these data indicate a marked increase in the exposure to bosentan and its primary metabolite Ro 48-5033 in patients with moderate liver function impairment (Child-Pugh class B).
Iako je broj uključenih bolesnika bio ograničen i s visokom varijabilnošću, ovi podaci naznačuju značajno povećanje izloženosti bosentanu i njegovom primarnom metabolitu Ro 48-5033 kod bolesnika s umjerenim oštećenjem jetre (Child- Pugh stadij B).
Thoughts about committing suicide
razmišljanja o samoubojstvu
Thoughts about committing suicide.
Razmišljanja o samoubojstvu
Thoughts about committing suicide.
Razmišljanja o samoubojstvu.
thoughts about suicide
razmišljanje o samoubojstvu
Thoughts about suicide or hurting yourself
misli o samoubojstvu i samoozljeđivanju
thoughts about threatening the life of others,
misli o ugrožavanju života drugih,
thoughts about threatening the life of others.
razmišljanja o ugrožavanju života drugih ljudi.
Thoughts of suicide and worsening of depression or anxiety disorder
Samoubilačke misli i pogoršanje depresije ili poremećaja tjeskobe
Thoughts of suicide and worsening of your depression or anxiety disorder
Samoubilačke misli i pogoršanje depresije ili anksioznog poremećaja
thoughts of suicide, suicide attempt and suicide,
misli o samoubojstvu, pokušaj samoubojstva i samoubojstvo;
thoughts of suicide, suicide attempt and suicide;
uicidalne misli, pokušaj samoubojstva i samoubojstvo;
Thread
Navoj
threaded needle connector
pojnica za iglu s navojima
threatening (grade 3-
opasne (stupanj 3
threatening events, including coma
događaja, uključujući komu (vidjeti
Three (3) patients with HES and CEL associated with PDGFR gene re-arrangements were reported in 3 publications.
U 3 publikacije zabilježena su 3 bolesnika s HES-om i KEL-om povezanim s preraspodjelom gena za PDGFR.
Three (3)patients with HES and CEL associated with PDGFR gene re-arrangements were reported in 3publications.
U 3 publikacije zabilježena su 3 bolesnika s HES-om i KEL-om povezanim s preraspodjelom gena za PDGFR.
Three (3)patients with HES and CEL associated with PDGFR gene re-arrangements were reported in 3publications.
U 3 publikacije zabilježenasu3 bolesnika s HES-om i KEL-om povezanim s preraspodjelom gena za PDGFR.
Three (<1%) out of 409 patients in the degarelix group and four (2%) out of 201 patients in the leuprorelin 7.5 mg group, had a QTcF ≥ 500 msec.
Tri (<1%) bolesnika od ukupno 409 u skupini koja je primala degareliks i četiri bolesnika (2%) od ukupno 201 u skupini koja je primala leuprorelin 7,5 mg, imali su QTcF ≥ 500 ms.
Three (<1%) out of 409 patients in the degarelix group and four (2%) out of 201 patients in the leuprorelin 7.5 mg group, had a QTcF ≥ 500 msec.
Tri (<1%) bolesnika od ukupno 409 u skupini koja je primala degareliks i četiri bolesnika (2%) od ukupno 201 u skupini koja je primala leuprorelin 7,5 mg, imali su QTcF ≥500 ms.
Three -weekly dosing in metastatic breast cancer
Trotjedni ciklusi u liječenju metastatskog raka dojke
Three 320 mg/40 mg tablets a day
Tri tablete od 320 mg/40 mg na dan
Three 5 mg tablets
tri tablete od 5 mg
Three additional studies were carried out to show that the active substances were absorbed in the body in the same way when they taken as separate tablets and as Rasilez HCT.
Provedena su tri dodatna ispitivanja kako bi se dokazalo da su djelatne tvari apsorbirane u tijelu na isti način kada se uzimaju kao zasebne tablete i kao lijek Rasilez HCT.
Three amine substituents at the macrocyclic lactone ring result in a tri-basic character of the molecule.
Tri aminska supstituenta na makrocikličkom laktonskom prstenu, rezultira trima glavnim osobinama molekule.
Three cases were consistent with LSCD, 6 had symptoms characteristic of LSCD and 5 may represent LSCD.
Tri su slučaja odgovarala LSCD-u, u 6 su bili prisutni simptomi karakteristični za LSCD, a 5 je moglo predstavljati LSCD.
Three clinical trials have been conducted in children and adolescents; two with standard interferon and ribavirin and one with pegylated interferon and ribavirin.
U djece i adolescenata provedena su tri klinička ispitivanja: dva sa standardnim interferonom i ribavirinom i jedno s pegiliranim interferonom i ribavirinom.
Three clinical trials were performed with Flebogamma DIF, one for replacement therapy in patients with primary immunodeficiency (in both adults and in children above 6 years) and two for immunomodulation, in patients with immune thrombocytopenic purpura (one in adult patients and another in both adult and children between 3 and 16 years).
Provedena su tri klinička ispitivanja s Flebogamma DIF-om; jedno za nadomjesnu terapiju u bolesnika s primarnom imunodeficijencijom (u odraslih i djece iznad 6 godina starosti) i dva ispitivanja za imunomodulaciju u bolesnika s imunološkom trompocitopeničnom purpurom (jedno u odraslih bolesnika i drugo u odraslih i djece u dobi između 3 i 16 godina).
Three clinical trials were performed with Flebogamma DIF, two for replacement therapy in patients with primary immunodeficiency (one in both adults and in children above 10 years and another in children between 2 to 16 years) and another for immunomodulation in adult patients with immune thrombocytopenic purpura.
Provedena su tri klinička ispitivanja s Flebogamma DIF-om; dva za nadomjesnu terapiju u bolesnika s primarnom imunodeficijencijom (jedno u odraslih i djece iznad 10 godina starosti, a drugo u djece u dobi između 2 i 16 godina) i jedno ispitivanje za imunomodulaciju u odraslih bolesnika s imunološkom trompocitopeničnom purpurom.
Three days before the infusion, a procedure called leukapheresis is performed to collect immune cells from the patient’s blood, and these are then sent to a manufacturing facility to prepare the medicine.
Tri dana prije infuzije provodi se postupak zvan leukafereza kako bi se prikupile stanice imunološkog sustava iz bolesnikove krvi i potom se iste šalju u proizvodni pogon da bi se pripremio lijek.
Three different doses of the medicine (10, 15 or 20 mg/day) were compared with placebo (a dummy treatment).
Tri različite doze lijeka (10, 15 ili 20 mg na dan) uspoređene su s placebom (prividnim liječenjem).
Three dogs had seizure-like activity ; however, relation to treatment could not be established.
U tri psa se pojavila aktivnost slična epileptičkom napadaju, međutim, nije se mogla utvrditi veza s terapijom.
Three dogs had seizure-like activity; however, relation to treatment could not be established.
U tri se psa pojavila aktivnost slična epileptičkom napadaju, međutim, nije se mogla utvrditi veza s terapijom.
Three doses each of 0.5 ml at 0, 1, 6 months**
Tri doze od 0,5 ml po rasporedu: 0, 1, 6 mjeseci
Three doses each of 0.5 ml, with first dose given at 2 months of age a
Tri doze svaka od 0,5 ml, prva doza daje se u dobi od 2 mjeseca a
Three doses of teduglutide, 0.0125 mg/kg/day (n=8), 0.025 mg/kg/day (n=14), and 0.05 mg/kg/day (n=15), were investigated for 12 weeks.
Tijekom 12 tjedana ispitivane su tri doze teduglutida: 0,0125 mg/kg/dan (n=8), 0,025 mg/kg/dan (n=14) i 0,05 mg/kg/dan (n=15).
three grey 20 mg
tri sive kapsule od 20 mg
Three implants per year are recommended;
Preporučuje se tri implantata godišnje, a maksimalan
Three independent, open-label, single arm, investigator-initiated studies with Myozyme were conducted:
Provedena su tri neovisna, otvorena, ispitivačem inicirana ispitivanja jedne grupe s lijekom Myozyme:
Three inserts, each with two 43.7mm openings per insert must be used.
Potrebno je koristiti tri uloška, svaki s otvorom od 43,7 mm po umetku.
Three large, international, open-label, non-controlled phase II studies were conducted in patients with Philadelphia chromosome positive (Ph+) CML in advanced, blast or accelerated phase disease, other Ph+ leukaemias or with CML in the chronic phase but failing prior interferon-alpha (IFN) therapy.
Tri velika, internacionalna, otvorena, nekontrolirana klinička ispitivanja faze II provedena su u bolesnika s Ph+ KML-om u uznapredovaloj, blastičnoj ili ubrzanoj fazi bolesti, drugim Ph+ leukemijama ili u bolesnika s KML-om u kroničnoj fazi, ali kojih nije uspjela prethodna terapija interferonom-alfa (IFN).
Three large, international, open-label, non-controlled phase II studies were conducted in patients with Philadelphia chromosome positive (Ph+) CML in advanced, blast or accelerated phase disease, other Ph+ leukaemias or with CML in the chronic phase but failing prior interferon-alpha (IFN) therapy.
Tri velika, internacionalna, otvorena, nekontrolirana klinička ispitivanja faze II provedena su u bolesnika s Ph+KML-om u uznapredovaloj,blastičnoj ili ubrzanoj fazi bolesti, drugim Ph+ leukemijama ili u bolesnika s KML-om u kroničnoj fazi, ali kojih nije uspjela prethodna terapija interferonom-alfa (IFN).
Three main studies involving 107 adults found that Pandemic influenza vaccine H5N1 MedImmune was able to prepare the immune system to defend itself against the H5N1 virus strain in individuals who had never come into contact with it.
Tri glavna ispitivanja koja su uključivala 107 odraslih osoba utvrdila su da cjepivo protiv pandemijske influence H5N1 MedImmune može pripremiti imunosni sustav da se obrani od soja virusa H5N1 u osoba koje nikada nisu došle u kontakt s tim virusom.
Three main studies of Lucentis involved 1,323 patients with the wet form of AMD.
Tri glavna ispitivanja uključivala su 1323 bolesnika s mokrim oblikom AMD-a.
Three main studies were carried out in adults with schizoaffective disorder.
Provedena su dva glavna ispitivanja u odraslih osoba oboljelih od shizoafektivnog poremećaja.
Three main studies were carried out with M-M-RVAXPRO.
Provedena su tri glavna ispitivanja s lijekom M-M-RVAXPRO.
Three major forms of interferons have been distinguished: alpha, beta and gamma.
Razlikuju se tri glavne skupine interferona: alfa, beta i gama.
Three major forms of interferons have been distinguished: alpha, beta, and gamma.
Ralikuju se tri glavne skupine interferona: alfa, beta i gama.
Three measuring spoons (green, pink, blue,) dispense, 100mg, 150mg or 1g of betaine anhydrous.
Tri mjerne žličice (zelena, ružičasta, plava) mjere, 100 mg, 150 mg ili 1 g bezvodnog betaina.
Three measuring spoons (pink, blue, green) dispense, respectively, 1 g, 150 mg and 100 mg of betaine anhydrous.
Tri mjerne žličice (ružičasta, plava, zelena) mjere redom 1 g, 150 mg i 100 mg bezvodnog betaina.
Three minor metabolites have been detected in human serum: (deaminohydroxy)toremifene, 4-hydroxytoremifene, and N,N-didemethyltoremifene.
U ljudskom serumu uočena su tri manje važna metabolita: (deaminohidroksi)toremifen, 4- hidroksitoremifen i N,N-didemetiltoremifen.
Three multi-centre, open-labelled, non-controlled trials have been conducted to evaluate the safety and efficacy of NovoEight in the prevention and treatment of bleeds in previously treated patients with severe haemophilia A (FVIII activity ≤1%).
Provedena su tri multicentrična, otvorena, nekontrolirana ispitivanja sigurnosti i djelotvornosti lijeka NovoEight u prevenciji i liječenju krvarenja u prethodno liječenih bolesnika s teškom hemofilijom A (aktivnost FVIII ≤1%).
Three of the efavirenz treatment failure isolates tested remained sensitive to efavirenz in cell culture and were also sensitive to nevirapine and delavirdine.
3 izolata dobivena od bolesnika u kojih je izostao odgovor na liječenje efavirenzom u staničnoj su kulturi i dalje bila osjetljiva na efavirenz, kao i na nevirapin i delavirdin.
Three of the efavirenz treatment failure isolates tested remained sensitive to efavirenz in cell culture and were also sensitive to nevirapine and delavirdine.
Tri izolata iz terapijskog neuspjeha efavirenza, in vivo, zadržala su u staničnoj kulturi osjetljivost na efavirenz kao i na nevirapin i delavirdin.
Three pack-sizes of Vargatef 100 mg soft capsules are available:
Dostupne su tri veličine pakiranja Vargatef 100 mg mekih kapsula:
Three patients (0.3%) experienced QTcF interval prolongation (greater than 500 ms).
Tri bolesnika (0,3%) imala su produljenje QTcF intervala (više od 500 ms).
Three patients had values above the upper limit of quantification (5 ng/mL) however they were already taking oral ciclosporin at a stable dose, which was allowed by the studies’ protocol.
Tri bolesnika imala su vrijednosti iznad gornje granice kvantifikacije (5 ng/ml) no oni su već uzimali stabilnu dozu ciklosporina oralno, što je bilo dopušteno protokolom ispitivanja.
Three patients in the Pradaxa group died (less than 1%), but two of these deaths were unrelated to blood clots.
U grupi koja je uzimala lijek Pradaxa umrla su tri bolesnika (manje od 1 %), no dva od ta tri smrtna slučaja nisu bila povezana s krvnim ugrušcima.
Three patients presented a complete haematological response (CHR) and one patient experienced a partial haematological response (PHR).
Tri bolesnika imala su kompletni hematološki odgovor (KHO), a jedan bolesnik je imao parcijalni hematološki odgovor (PHO).
Three patients were not evaluable for response in Study 1001, and 42 patients were not evaluable for response in Study 1005.
Nije se mogao procijeniti odgovor u 3 bolesnika u Ispitivanju 1001 te u 42 bolesnika u Ispitivanju 1005.
Three patients with emergent HIV-1 resistance to Genvoya were identified (M184M/I; M184I+E92G; M184V+E92Q) up to Week 96 in a clinical study of virologically suppressed patients who switched from a regimen containing emtricitabine/tenofovir disoproxil fumarate and a third agent (GS-US-292-0109, n = 959).
U kliničkom ispitivanju u bolesnika kod kojih je virus suprimiran te koji su prešli s režima koji sadrži emtricitabin/tenofovirdizoproksilfumarat i treći lijek (GS-US-292-0109, n = 959), do 96. tjedna identificirana su tri bolesnika s novonastalom rezistencijom HIV-1 (M184M/I; M184I+E92G; M184V+E92Q) na lijek Genvoya.
Three patients, including 2 patients with a Grade 3 case, received high-dose corticosteroids (at least 40 mg prednisone equivalents) at a median initial dose of 0.6 mg/kg (range: 0.4-1.3) for a median duration of 2.0 weeks (range: 1.4-14.1).
bolesnika sa slučajem 3. stupnja, primala visoke doze kortikosteroida (najmanje 40 mg ekvivalenata prednizona), uz medijan početne doze od 0,6 mg/kg (raspon: 0,4-1,3), tijekom medijana od 2,0 tjedna (raspon: 1,4-14,1).
Three phase III randomised, double-blind studies (HZA106827, HZA106829 and HZA106837) of different durations evaluated the safety and efficacy of fluticasone furoate/vilanterol in adult and adolescent patients with persistent asthma.
U tri randomizirana, dvostruko slijepa ispitivanja faze III (HZA106827, HZA106829 i HZA106837) različitih trajanja ocjenjivala se sigurnost i djelotvornost flutikazonfuroata/vilanterola u odraslih osoba i adolescenata s trajnom astmom.
Three pivotal studies were conducted to assess the efficacy and safety of NEVANAC dosed 3 times daily as compared to vehicle and/or ketorolac trometamol in the prevention and treatment of postoperative pain and inflammation in patients undergoing cataract surgery.
Provedena su tri pivotalna ispitivanja za ocjenu djelotvornosti i sigurnosti NEVANAC-a koji je doziran 3 puta dnevno, u usporedbi s podlogom lijeka i/ili ketorolak trometamolom za prevenciju i liječenje postoperativne boli i upale u bolesnika koji su pripremani za operaciju katarakte.
Three Pixuvri patients (4.4%) had tachycardia, arrhythmia, sinus tachycardia, or bradycardia.
Tri bolesnika u skupini Pixuvria (4,4%) imala su tahikardiju, aritmiju, sinusni tahikardiju ili bradikardiju.
Three placebo-controlled phase III studies in plaque psoriasis were integrated to evaluate the safety of Taltz in comparison to placebo up to 12 weeks after treatment initiation.
Podaci iz tri placebom kontrolirana ispitivanja faze III provedena u bolesnika s plak psorijazom objedinjeni su radi ocjene sigurnosti lijeka Taltz u usporedbi s placebom tijekom razdoblja do 12 tjedana nakon početka liječenja.
Three presentations are available:
Dostupne su tri veličine pakiranja:
three pump actuations
tri pokretanja pumpice
three pump actuations
tri potiska pumpice
Three recommended injection sites for Enbrel using a pre-filled syringe include: (1) the front of the middle thighs; (2) the abdomen, except for the 5 cm area right around the navel; and (3) the outer area of the upper arms (see Diagram 1).
Tri preporučena mjesta za injekciju Enbrela pomoću napunjen štrcaljke uključuju: (1) prednju stranu sredine natkoljenice, (2) trbuh, s iznimkom područja u krugu 5 cm oko pupka te (3) vanjsku stranu nadlaktice (vidjeti sliku 1).
Three recommended injection sites for Nplate include:
Tri mjesta za injekciju lijeka Nplate koja se preporučuju su:
Three side effects are possibly related to the medicine’s toxic effect on mitochondria (the energy- producing components within cells): lipoatrophy, lactic acidosis (a build-up of lactic acid in the body) and peripheral neuropathy.
Postoji mogućnost da su tri nuspojave povezane s toksičnim učinkom lijeka na mitohondrije (sastavni dijelovi stanica koji proizvode energiju): lipoatrofija, laktacidoza (nakupljanje mliječne kiseline u tijelu) i periferna neuropatija.
Three studies were conducted in men to assess the potential effect on spermatogenesis of tadalafil 10 mg (one 6-month study) and 20 mg (one 6-month and one 9-month study) administered daily.
Provedena su tri ispitivanja u muškaraca kako bi se procijenio potencijalni utjecaj svakodnevne primjene. u dozi od 10 mg (jedno 6-mjesečno ispitivanje) i 20 mg (jedno 6-mjesečno i jedno 9- mjesečno ispitivanje) na spermatogenezu.
Three studies were ‘open’, meaning that the medicine was not compared to any other treatment and the patients knew that they were receiving Hycamtin.
Tri ispitivanja su bila "otvorena", što znači da se lijek ne može usporediti s bilo kojim drugim liječenjem, te su bolesnici znali da primaju Hycamtin.
Three therapeutic studies performed in PD patients without any tyramine restriction, also did not detect any evidence of tyramine potentiation.
Tri terapijska ispitivanja provedena na bolesnicima s PB-om bez ograničenja tiramina također nisu otkrila nikakve dokaze pojačavanja učinka tiramina.
three times a day
0,088 mg tri puta dnevno
three times a day
0,18 mg tri puta dnevno
three times a day
0,35 mg tri puta dnevno
three times daily
puta na dan
three times daily)
triput na dan)
Three times per day
Tri puta dnevno
Three to six months are required after the initiation of therapy for equilibration to occur.
Potrebno je tri do šest mjeseci kako bi se postigla ravnoteža nakon početka terapije.
Three to six months are required after the initiation of therapy for equilibration to occur.
Za uspostavljanje ravnoteže, potrebno je tri do šest mjeseci od početka terapije.
Three, 6 month, double-blind, placebo-controlled clinical studies were conducted in ESRD patients with uncontrolled secondary HPT receiving dialysis (n=1136).
Tri šestomjesečne, dvostruko slijepe, placebo kontrolirane studije provedene su u bolesnika s terminalnom bolesti bubrega i nekontroliranim sekundarnim HPT-om na dijalizi (n=1136).
Three, 6-month, double-blind, placebo-controlled clinical studies were conducted in ESRD patients with uncontrolled secondary HPT receiving dialysis (n=1136).
Tri šestomjesečne, dvostruko slijepe, placebo kontrolirane studije provedene su u bolesnika s terminalnom bolesti bubrega i nekontroliranim sekundarnim HPT-om na dijalizi (n=1136).
Three-dose primary series
Primarna imunizacija s tri doze
Three-sigma threshold value
Tri sigma vrijednost praga
Three-weekly schedule
Trotjedni ciklusi
throat and mouth yeast infection vaginal infection
gljivična infekcija grla i usta vaginalna infekcija
throat infection
infekcija grla
throat infections  dry eyes
infekcije grla  suhe oči
throat inflammation that causes a hoarse voice
upala grla koja uzrokuje promuklost
throat inflammation that causes a hoarse voice;
upala grla koja uzrokuje promuklost
Throat irritation
Nadražaj grla
Throat irritation
Nadraženo grlo
Throat irritation
Nadraženost grla
throat irritation, throat tightness, lip swelling, tongue swelling injection site discolouration, injection site itching and discolouration
nadraženost grla, stezanje u grlu, oticanje usana, oticanje jezika promjena boje kože na mjestu davanja injekcije, svrbež i promjena boje kože na mjestu primjene injekcije.
Throat pain
bol u grlu
throat pain
grlobolja
throat pain or irritation
bol ili iritacija grla
Throat pain, snoring
gol u grlu, hrkanje
throat redness*
crvenilo grla
Throat tightness
tezanje u grlu
Throat tightness Epistaxis
stezanje u grlu epistaksa
throat tightness generalized itching
zatezanje u grlu generalizirani svrbež
Throat tightness, hiccups, throat irritation,
stezanje u grlu, štucanje, nadraženost grla,
throat tightness, nose bleeds
tezanje u grlu, krvarenja iz nosa